Walker

[Tom Angell 🌳📰ⓥ @tomangell]

👀👀👀

The Department of Justice filed a brief opposing a drug testing industry group and a pharmaceutical company's motion to pause cannabis rescheduling—pointing out that they have "pocketbook interests served by keeping all marijuana in schedule I."

https://t.co/OJ1zPqTe28

[Walker @Walker332333]

@GerberKawasaki @hatemdhiab I did. We have a career business man in office instead of a career do-nothing politician. Trump gets it….

[Walker @Walker332333]

@RepDaveJoyce Great - let’s see how incompetent congress is for the 8th time. Can’t wait for this to go nowhere again.

[Anthony Varrell @V_arrell]

Onward. 👏👏👏 @rivers_kim $TRLV

https://t.co/KnBaceWkFn

[Dave Joyce @RepDaveJoyce]

As President Trump has emphasized, debanking has hurt legal businesses across the country.

I reintroduced the SAFE Banking Act to keep our communities safe by ensuring state-legal businesses have access to the financial services they need to succeed.

https://t.co/vOvVeebpOR

[Walker @Walker332333]

@rivers_kim @Trulieve Thanks for killing the uplist momentum. From your stock sale to firing and then rehiring the President - amateur hour to say the least.

I’ve held your stock and continually bought more for the past 5 years - worst financial decision I’ve ever made.

[Brandon Herrera @TheAKGuy]

Higher T levels will cost the Democrats more votes than the SAVE Act.

[Massimo @Rainmaker1973]

A U.S. cannabis company has joined the New York Stock Exchange for the first time in history. Trulieve, a Florida-based operator, has made history as the first American cannabis business to trade on the NYSE, representing a major milestone in the industry’s acceptance by regulators, investors, and the scientific community.

For decades, marijuana’s classification as a Schedule I substance under federal law created significant obstacles for cannabis companies. Despite the rapid growth of medical and recreational markets across the country, most U.S. cannabis firms were barred from major American stock exchanges and were forced to list on smaller over-the-counter markets or move to Canadian exchanges.

That landscape is now shifting. The listing comes after the federal government rescheduled medical marijuana from Schedule I to Schedule III. Schedule I drugs are defined as having no accepted medical use and high potential for abuse (including substances like heroin and LSD). Schedule III substances, by contrast, have recognized medical applications and face fewer regulatory restrictions.

While this move does not legalize cannabis federally, recreational use remains illegal at the national level, it carries important scientific and financial consequences.

Researchers have long maintained that Schedule I restrictions severely limited rigorous clinical studies on cannabis. Scientists faced heavy bureaucratic hurdles when attempting to study its medical potential, optimal dosing, long-term effects, and interactions with other drugs.

With the new classification, universities and research institutions are expected to pursue more comprehensive clinical trials. This could finally produce stronger, evidence-based data on cannabis’s effectiveness for conditions such as chronic pain, epilepsy, and various neurological disorders.

For investors, Trulieve’s NYSE listing represents a clear signal that cannabis is entering mainstream financial markets. For the scientific community, it opens the door to studies that were previously extremely difficult to conduct.

Regardless of one’s stance on marijuana legalization, it is becoming evident that the future of cannabis will be shaped increasingly by scientific research and empirical data, rather than politics alone.

[Mario Nawfal @MarioNawfal]

🇺🇸 Trulieve ($TRLV) is now trading on the NYSE.

It's the first major U.S. cannabis operator to secure a listing on a premier U.S. exchange: a milestone many thought was still years away.

The cannabis industry just took a major step toward the financial mainstream.

Writer: Val

[Walker @Walker332333]

@MitchGordon_ @CNBC @NYSE @jimcramer @carlquintanilla @SquawkStreet You would think Tim Seymour would have her on.

[Walker @Walker332333]

@realpristinecap Great job!

[Walker @Walker332333]

@AlderLaneEggs @Bkov9 @rivers_kim Constantly talking shit about people that have never done anything to you (and only helped this industry’s cause) is a very feminine trait. I think you need some TRT or maybe just shut up - it’s getting ridiculous.

[Trulieve_IR @Trulieve_IR]

Trulieve Announces Share Repurchase Program $TRUL $TCNNF https://t.co/0RE84fTUkI

[Market Wire News @marketwirenews]

$TCNNF - The Single Biggest Cannabis Catalyst in Years Is Rapidly Approaching 2 Marijuana Stocks to Buy Now

2026-06-07 00:35:00 ET A sea change is taking place for cannabis companies , one that will have an enormous benefit for the industry. … https://t.co/cukTu6N587

[MosleyTribes @mosley_tribes]

$MSOS high level valuation update

With uplisting's coming, if the OTC MSO names re-rate to $CURLF's (TSX listed) EV/EBITDA multiple, here's what happens to the share price:
$VRNOF: $1.17 → $6.67 (+470%)
$GTBIF: $8.20 → $24.67 (+201%)
$TCNNF: $11.74 → $26.04 (+122%)

[Walker @Walker332333]

@MSOinvest The majority of capex going forward will be to expand their medical business which is the highest margin - GA & TX will be huge.

[Kim Rivers @rivers_kim]

Thank you @Forbes and @AJHerrington1 for covering @Trulieve’s historic @NYSE listing news! The best is yet to come! https://t.co/CzYcrM2nnt

[Walker @Walker332333]

@Lifeisshort8888 @V_arrell Perfect - thank you!

[Walker @Walker332333]

@HempMillionaire @TheDankInformer It’s called capitalism dick-weed